Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04899128
Status:
UNKNOWN
Last Update Posted:
2021-05-24
First Post:
2021-05-19
Brief Title:
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer A Real World Study
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter observational single-arm real world study to evaluate the efficacy and safety of pyrotinib after lapatinib progression
Detailed Description:
HER2-positive breast cancers account for 15-20 of all breast cancers The development of HER2 targeted therapies have greatly improved the survival of HER2-positive breast cancer patients Lapatinib has shown effectiveness in treating HER2-positive metastatic breast cancers but therapies after lapatinib progression are still controversial This study is aimed to evaluate the efficacy and safety of pyrotinib after lapatinib progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None